Across TCGA pan-cancer cohorts, TFPT Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TFPT data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TFPT Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TFPT expression acts as an unfavorable survival marker.
STAD and ACC are the cancer types where TFPT Mutation most reproducibly stratifies survival.